<DOC>
	<DOCNO>NCT02214407</DOCNO>
	<brief_summary>This phase III , two-arm , randomize , stratify , multicenter , open-label study individual therapeutic benefit aim : Decitabine ( DAC ) without Hydroxyurea ( HY ) versus HY patient advance proliferative Chronic Myelomonocytic Leukemia ( CMML ) The primary objective study compare two arm Event-free Survival ( EFS ) . Secondary objective compare arm : Overall Survival ( OS ) Cumulative incidence AML Overall Complete Response Rates 3 6 cycle accord IWG 2006 criterion modify CMML Response duration Toxicity ( hematological non hematological ) Prognostic factor</brief_summary>
	<brief_title>Randomized Phase III Study Decitabine +/- Hydroxyurea ( HY ) Versus HY Advanced Proliferative CMML</brief_title>
	<detailed_description>ARM A : DECITABINE ( DAC ) Decitabine ( DAC ) administer 20 mg/m2 intravenously daily 5 day every 28 day . Treatment delayed discretion investigator ( D56 ) febrile neutropenia ( ≥ 38.5°C ; absolute neutrophil count [ ANC ] , &lt; 1,000/μL ) , clinical and/or microbiologic infection grade 3 4 neutropenia ( ANC &lt; 1,000/μL ) , hemorrhage grade 4 thrombocytopenia ( &lt; 25,000 platelets/μL ) . If renal hepatic dysfunction occur , treatment stop resolution withheld dysfunction persist 4 day . Persistent grade 4 thrombocytopenia neutropenia beyond D49 mandate bone marrow evaluation . Treatment continue event reach . Events thus study exit acknowledge agreement investigator Trial Committee . Allopurinol , 300mg/d , start time inclusion ; hydration treatment administer patient . In ( rare ) case necessity , prophylactic anti-emetics could give . Hydroxyurea may add first 3 cycle WBC count &gt; 30 G/L , mandatory WBC &gt; 50 G/L . The daily dose adapt maintain WBC 15 20 G/L . ARM B : HYDROXYUREA ( HY ) Hydroxyurea ( HY ) 1g/d daily , dose adjustment ( 4g/d ) maintain WBC count 5 10 G/L . Allopurinol , 300mg/d start time inclusion administer patient . Treatment continue event reach . Events thus study exit acknowledge agreement investigator Trial Committee . This intended prevent early dropout , notably HY arm . Dose escalation perform step 0.5 g/d , 4 g/d , WBC reduce less 20 % remain &gt; 15 G/L . HY adapt maintain WBC count 5 10 G/L . HY lower platelet decrease &gt; 30 X 109/L ( initially 100 X 109L ) . HY discontinue case grade 4 thrombocytopenia neutropenia , reintroduce low dose recovery grade ≤ 3 . Persistent grade 4 thrombocytopenia neutropenia 4 week discontinuation mandate bone marrow evaluation .</detailed_description>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Benzocaine</mesh_term>
	<criteria>Age ≥ 18 CMML diagnosis accord WHO criteria Stable excess blood monocyte , &gt; 1 G/L Lack bcrabl rearrangement ( Philadelphia chromosome ) Bone marrow blast cell &lt; 20 % Dysplasia least one lineage clonality marker blood monocytosis 3 month w/o explanation Blood marrow smear review country 's level , morphologist meeting 3 country level plan well harmonization review difficult case WBC ≥ 13 G/L Measured two successive CBC least two week apart , outside context infection . Either D1 D2 D1 : At least two follow criterion , review country 's level : ( modified Wattel et al . Blood 1996 ) Marrow blast &gt; = 5 % Clonal cytogenetic abnormality ( ( 5 ; 12 ) ( q33 ; p13 ) isolated loss Y chromosome ) Anemia ( Hb &lt; 10 g/dL ) ANC &gt; 16 G/l ( absence infection ) Thrombocytopenia ( platelet count &lt; 100 G/L ) Splenomegaly &gt; 5 cm costal margin ( spleen size also measure image technique ) Or : D2 : Extramedullary involvement : Including document cutaneous , pleural pericardial effusion . No prior treatment ( except supportive care , ESA , short term ( &lt; 6 week ) HY patient present high WBC count ) Performance status 02 Eastern Cooperative Oncology Group ( ECOG ) Scale . Adequate organ function include follow Hepatic : total bilirubin &lt; 1.5 time upper limit normal ( ULN ) ( except moderate unconjugated hyperbilirubinemia due intra medullary hemolysis Gilbert syndrome ) , alanine transaminase ( ALT ) aspartate transaminase ( AST ) &lt; 3xULN Renal : serum creatinine &lt; 2 x ULN Signed Informed consent Negative pregnancy adequate contraception ( include male patient wish father ) relevant . Myeloproliferative / myelodysplastic syndrome CMML CMML ( 5 ; 12 ) PDGFBR rearrangement may receive imatinib Patients eligible allogeneic bone marrow transplantation identify donor Pregnant breastfeeding Performance status &gt; 2 ECOG Scale . Serious concomitant systemic disorder , include active bacterial , fungal viral infection opinion investigator would compromise safety patient and/or his/her ability complete study Prior malignancy ( except situ cervix carcinoma , limited basal cell carcinoma , tumor active last 3 year )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>